aTyr Pharma, Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
aTyr Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines based on tRNA synthetase biology. The company’s current work centers on efzofitimod, a selective NRP2 modulator being studied for interstitial lung diseases, including pulmonary sarcoidosis and systemic sclerosis-related ILD. aTyr Pharma also advances preclinical programs such as ATYR0101 for fibrosis and ATYR0750 for liver disorders, reflecting a pipeline aimed at inflammation, immune regulation, and tissue remodeling. Headquartered in San Diego, California, and founded in 2005, aTyr Pharma operates as a research-driven biopharmaceutical company with a focus on translating proprietary biology into potential therapeutic candidates for serious fibrotic and inflammatory conditions.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Sanjay S. Shukla M.D., M.S.
- Employees
- 58
- Headquarters
- San Diego, CA, United States
- Website
- atyrpharma.com